Now that Myriad Genetics, Inc.’s volume has hit 0.8 million, investors get a glimpse of its size.

QCOM

On Tuesday, Myriad Genetics, Inc. (NASDAQ: MYGN) was 3.30% up from the session before settling in for the closing price of $23.97. A 52-week range for MYGN has been $13.82 – $25.95.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 4.63% over the past five years. When this article was written, the company’s average yearly earnings per share was at 111.11%. With a float of $86.78 million, this company’s outstanding shares have now reached $89.90 million.

Let’s look at the performance matrix of the company that is accounted for 2700 employees.

Myriad Genetics, Inc. (MYGN) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Myriad Genetics, Inc. stocks. The insider ownership of Myriad Genetics, Inc. is 4.12%, while institutional ownership is 104.73%. The most recent insider transaction that took place on Jun 04 ’24, was worth 83,525. In this transaction Director of this company sold 3,788 shares at a rate of $22.05, taking the stock ownership to the 32,917 shares. Before that another transaction happened on Jun 03 ’24, when Company’s Director sold 3,788 for $22.04, making the entire transaction worth $83,488. This insider now owns 36,705 shares in total.

Myriad Genetics, Inc. (MYGN) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around 111.11% per share during the next fiscal year.

Myriad Genetics, Inc. (NASDAQ: MYGN) Trading Performance Indicators

You can see what Myriad Genetics, Inc. (MYGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.89.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.21 in one year’s time.

Technical Analysis of Myriad Genetics, Inc. (MYGN)

Myriad Genetics, Inc. (NASDAQ: MYGN) saw its 5-day average volume 0.77 million, a positive change from its year-to-date volume of 0.71 million. As of the previous 9 days, the stock’s Stochastic %D was 66.66%. Additionally, its Average True Range was 0.93.

During the past 100 days, Myriad Genetics, Inc.’s (MYGN) raw stochastic average was set at 85.22%, which indicates a significant decrease from 88.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 30.21% in the past 14 days, which was lower than the 52.12% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $22.67, while its 200-day Moving Average is $20.08. Nevertheless, the first resistance level for the watch stands at $25.31 in the near term. At $25.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $26.63. If the price goes on to break the first support level at $23.99, it is likely to go to the next support level at $23.21. Assuming the price breaks the second support level, the third support level stands at $22.67.

Myriad Genetics, Inc. (NASDAQ: MYGN) Key Stats

There are 90,508K outstanding shares of the company, which has a market capitalization of 2.24 billion. As of now, sales total 753,200 K while income totals -263,300 K. Its latest quarter income was 202,200 K while its last quarter net income were -26,000 K.